Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Gastrointestinal Cancer
Published in: Journal of Gastrointestinal Cancer 3/2017

01-09-2017 | Original Research

Validation of a Liver Index and Its Significance for HCC Aggressiveness

Authors: Brian I. Carr, Vito Guerra

Published in: Journal of Gastrointestinal Cancer | Issue 3/2017

Login to get access

Abstract

Background

We recently constructed a liver index (LI) from four liver parameters, namely: blood total bilirubin, gamma glutamyl transpeptidase (GGTP), albumin, and platelet levels (a cirrhosis surrogate). We found that the scores for the liver index related significantly to a four-parameter HCC aggressiveness index (maximum tumor diameter, multifocality, percent portal vein invasion, and blood AFP levels).

Aims

To validate the relationship of liver parameters to tumor aggressiveness parameters in a larger, different HCC dataset.

Results

We now confirm these associations in another large HCC cohort. Furthermore, this liver index showed significant trends with the individual HCC aggressiveness parameters.

Conclusions

These results provide further support for the idea that liver microenvironment, as reflected in liver function tests, may relate to HCC behavior.
Literature
1.
Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918–28.CrossRef
2.
Memon K, Kulik LM, Lewandowski RJ, Wang E, et al. Comparative study of staging systems for hepatocellular carcinoma in 428 patients treated with radioembolization. J Vasc Interv Radiol. 2014;25:1056–66.CrossRef
3.
Carr BI, Guerra V, Giannini EG, Farinati F, et al. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. Semin Oncol. 2014;41:252–8.CrossRef
4.
Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512–27.CrossRef
5.
Carr BI, Guerra VA. Hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology. 2016;90:215–20.CrossRef
6.
7.
Carr BI, Guerra V, Giannini EG, Farinati F, et al. A liver index and its relationship to indices of HCC aggressiveness. J Integr Oncol. 2016;5:3.
8.
Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol. 2014;41:415–21.CrossRef
9.
Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D’Onofrio M, et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008;103:597–604.CrossRef
10.
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8.CrossRef
11.
Kinoshita A, Onoda H, Imai N, Iwaku A. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:52.CrossRef
12.
Nojiri S, Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci. 2014;15:5163–74.CrossRef
13.
14.
Lu SN, Wang JH, Liu SL, Hung CH, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006;107:2212–22.CrossRef
15.
D'Alessandro R, Refolo MG, Lippolis C, Giannuzzi G, et al. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer. 2014;14:351.CrossRef
16.
Ma H, Zhang L, Tang B, Wang Y, et al. γ-Glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma. Ann Surg Oncol. 2014;21:3084–9.CrossRef
17.
Carr BI, Pancoska P, Branch RA. Significance of increased serum GGTP levels in HCC patients. Hepato-Gastroenterology. 2010;57:869–74.PubMed
18.
Pancoska P, Carr BI, Branch RA. Network-based analysis of survival for unresectable hepatocellular carcinoma. Semin Oncol. 2010;37:170–80.CrossRef
19.
Utsunomiya T, Shimada M, Imura S, Morine Y, et al. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol. 2010;45:146–52.CrossRef
20.
Hanigan MH, Gallagher HC, Townsend DM, Gabarra V. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo. Carcinogenesis. 1999;20:553–9.CrossRef
21.
Toyoda H, Kumada T, Tada T, Sone Y, et al. Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer. 2015;4:126–36.CrossRef
Metadata
Title
Validation of a Liver Index and Its Significance for HCC Aggressiveness
Authors
Brian I. Carr
Vito Guerra
Publication date
01-09-2017
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 3/2017
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-017-9971-4

Other articles of this Issue 3/2017

Journal of Gastrointestinal Cancer 3/2017 Go to the issue

Review Article

Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis

Review Article

Hepatocellular Cancer: Is Recurrence Inevitable?

Review Article

HCC Locoregional Therapies: Yttrium-90 (Y-90) Selective Internal Radiation Therapy (SIRT)

Review Article

Is That Possible to Stop or Cease the NASH to Turn into HCC?

Review Article

Liver Transplantation for Hepatocellular Carcinoma at Inonu University

Review Article

Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits